



Approaches for capital injection

1) High FOMO-factor

The company's value has been officially certified by a reputable New York accounting and law firm at \$3.5 million (pre-money).

- Message: You are investing in a validated international business, not an early-stage garage company. We have already generated revenue for years in our European business, and the enzyme concept has been proven. The value of our company will grow rapidly in the first few years through scaling in Brazil, followed by the US and international markets.

2) Proven de-risking

The technologies that provide the foundation for the business have been successfully reviewed and vetted by leading scientists at the federal (National Science Foundation), state (State of Florida), and Intergovernmental levels and have been awarded grant opportunities. Numerous independent tests and scientific studies demonstrate the effectiveness of our technology. Following thorough due diligence by a leading investment bank, which included an investigation of our technology, market opportunities, competition, industry trends, and valuation, we established that our value is viable for financial products. As a result, we received an offer and an engagement agreement.

- Message: The primary risk regarding product functionality has been addressed. The capital is intended solely to expedite and boost commercialization and logistics for market entry. With increased capital, we can achieve better results more quickly and enhance ROI.

3) Quick turnaround times (cash-flow)

Four environmental projects are available for immediate launch. A blue-green algae treatment project has a cost of goods sold (COGS) of \$300,000 and an expected revenue of \$2.5 – \$3.0 million – in just 1 month. Environmental cleanup projects using enzyme-based biological degradation are typically completed within two weeks, depending on the size of the treated area. After the control measurement, the buyer will see the results, and we can then send our invoice.


- Message: We are involved in several project lines focused on environmental cleanup. We have identified the sources of these problems and have local connections and experts who can assist us throughout the process. Some of them are standalone projects; others are contractual jobs in which we create a revenue stream through maintenance applications. Our existing evidence has already established a reputation for us in certain circles. However, once we enhance our portfolio with successfully completed projects, we will open new doors and gain approval for many other initiatives in the global marketplace.

In the product manufacturing and distribution industries, we enter markets where demand is high, competition is low, and our marketing communications effectively highlight our selling points.

4) Ready market in agriculture

Some selected Brazilian model farms have submitted letters of intent and are prepared to pay a deposit after completing the short tests. The buyers are already lined up.

- Message: There are open doors. We do not need to explain to farmers why the active living enzyme culture of earthworms is beneficial for the soil. No competition can surpass us in this regard.



5) CONCLUSION

We are not asking for funding for just an idea.

We are not seeking funding for an unproven initiative or a business that has failed to deliver results.

Reaching this point has been a valuable journey and an important learning experience. We now have a clear understanding of what works, what does not, and what is required to succeed. Our investment partner will benefit from this accumulated knowledge and practical experience, which cannot be developed overnight. The challenges we encountered helped shape a stronger and more resilient organization. These setbacks were not the result of shortcomings in our technology, but primarily reflected external circumstances, market conditions, and the realities of the environment in which we operate. We also learned that some individuals, organizations, and government bodies may benefit from maintaining the status quo, and the problem, creating limited incentives to support technologies designed to resolve persistent problems. Recognizing these conflicts of interest prompted us to develop a more effective and sustainable path forward. Our approach is designed to generate profit while remaining true to our core mission: improving human health and protecting the environment.

We have a validated technology worth \$3.5 million, confirmed by independent entities and U.S. government agencies, along with a ready queue of customers. In its current established state, our technology is theoretically valued at \$475 million,” stated James Gormley AEE, after he thoroughly investigated our technologies. He was an inventor-scientist recognized by the scientific community and organizations and known for his leadership as the Chairman of the Strategic Technology Alliance, the UN, and Green Cross.

Moreover, a leading investment bank investigated the business opportunity we presented. After conducting their in-house due diligence, we received approval as a financial product for raising funds.

The capital is needed to build the logistics bridge and infrastructure, scale up operations, realize immediate high-value projects, and advance agricultural initiatives and environmental initiatives.

You are not investing in risk; you are buying a share in an emerging, disruptive global biotechnology revolution.